Synthesis and in vitro study of cisplatin-loaded Fe3O4 nanoparticles modified with PLGA-PEG6000 copolymers in treatment of lung cancer

Journal of Microencapsulation

Volumn 31, Issue 8, 2014, Pages 815-823

  Nejati Koshki, Kazem ^a,b   Mesgari, Mehran ^a,b   Ebrahimi, Eommolbanin ^a   Abbasalizadeh, Farhad ^a,b   Aval, Sedigeh Fekri ^a,b   Khandaghi, Amir Ahmad ^b   Abasi, Mozhgan ^b   Akbarzadeh, Abolfazl ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cisplatin; Drug delivery; Lung cancer; Magnetic nanoparticles; PLGA PEG

Indexed keywords

CISPLATIN; IRON OXIDE NANOPARTICLE; MACROGOL 6000; MAGNETIC NANOPARTICLE; POLYGLACTIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FERRIC ION; FERRIC OXIDE; LACTIC ACID; MACROGOL DERIVATIVE; MAGNETITE NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INFRARED SPECTROSCOPY; LUNG CANCER; PARTICLE SIZE; POLYMERIZATION; ROOM TEMPERATURE; SCANNING ELECTRON MICROSCOPY; STEREOSPECIFICITY; SUSTAINED DRUG RELEASE; X RAY DIFFRACTION; X RAY POWDER DIFFRACTION; CHEMISTRY; DRUG SCREENING; LUNG NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FERRIC COMPOUNDS; HUMANS; LACTIC ACID; LUNG NEOPLASMS; MAGNETITE NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID;

EID: 84910032779     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2014.940011     Document Type: Article

References (42)

1. 4 magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomed, 2012a;7:511-26.
2. Abolfazl A, Nosratollah Z, Haleh M, Davoud A, Amir M, Goganian H, Khaksar K, Soodabeh D. Synthesis, characterization and in vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled delivery of doxorubicin. Int J Nanotechnol Sci Environ, 2012b;5:13-25.
3. Abolfazl A, Samiei M, Soodabeh D. Magnetic nanoparticles: Preparation, physical properties and applications in biomedicine. Nanoscale Res Lett, 2012c;7:144-57.
4. Abolfazl A, Kazem N-K, Mahsa MS, Somayeh A, Mahmoud FG, Soodabeh D. In vitro studies of NIPAAM-MAA-VP copolymer-coated magnetic nanoparticles for controlled anticancer drug release. J Encapsul Adsorp Sci, 2013a;3:108-15.
5. Abolfazl A, Rogaie R-S, Soodabeh D, Sang WJ, Nosratollah Z, Younes H, Mohammad S, Mohammad K, Kazem N-K. Liposome: Classification, preparation, and applications. Nanoscale Res Lett, 2013b;8:102-10.
6. Abolfazl A, Akbar R, Kazem N-K, Somayeh A, Soodabeh D. Synthesis and physicochemical characterization of biodegradable star-shaped poly lactide-co-glycolide-b-cyclodextrin copolymer nanoparticles containing albumin. Adv Nanopart, 2014;3:14-22.
7. Ahmadi A, Shirazi H, Pourbagher N, Akbarzadeh A, Omidfar K. An electrochemical immunosensor for digoxin using core-shell gold coated magnetic nanoparticles as labels. Mol Biol Rep, 2014;41(3):1659-68.
8. Akbarzadeh A, Samiei M, Joo SW, Anzaby M, Hanifehpour Y, Nasrabadi HT, Davaran S. Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. J Nanobiotechnol, 2012;10:46-58.
9. Ali E, Hadis D, Nosratolah Z, Hassan MY, Abolfazl A, Younes H. Nanofiber; Synthesis and biomedical applications. Artificial Cells, Nanomed Biotechnol, 2014;43:1-11.
10. Alireza V, Haleh M, Mohammad S, Samad MF, Nosratollah Z, Mohammad K, Abolfazl A, Soodabeh D. Quantum dots: Synthesis, bioapplications, and toxicity. Nanoscale Res Lett, 2012;7:276 (1-14).
11. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med, 2000;342(8):564-71.
12. Comis RL. Cisplatin: The future. Semin Oncol, 1994;21:109-13.
13. Effat A, Nosratollah Z, Mohammad RBE, Abolfazl A, Shahrbano J, Abolfazl B, Shahryar H, Abolghasem M. The effect of dimethyl sulfoxide on hepatogenic differentiation of mesenchymal stem cells. Int J Pediatr, 2014;43(2):57-8.
14. Elham A, Morteza M, Sedigheh FA, Mohammad K, Abolfazl A, Hamid TN, Parisa N, San WJ, Younes H, Kazem N-K, Mohammad S. Silver nanoparticles: Synthesis, properties, bio-applications and limitations. Crit Rev Microbiol, 2014a;43:1-8.
15. Elham A, Sedigheh FA, Abolfazl A, Morteza M, Hamid TN, San WJ, Younes H, Kazem N-K. Dendrimers: Synthesis, applications and properties. Nanoscale Res Lett, 2014b;9:247-56.
16. Ely L, Roa W, Finlay WH, Löbenberg R. Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm, 2007;65(3):346-53.
17. Farajnia S, Hassan M, Hallaj Nezhadi S, Mohammadnejad L, Milani M, Lotfipour F. Determination of indicator bacteria in pharmaceutical samples by multiplex PCR. J Rapid Meth Automat Microbiol, 2009;17(3):328-38.
18. Fatemeh S, Tabatabaei M, Abolfazl A, Nosratollah Z, Vahideh Z, Amirbahman R, Somayeh A. PLGA-cased nanoparticles as cancer drug delivery systems. APJCP. Asian Pac J Cancer Prev, 2014;15(1):517-35.
19. Ghasemali S, Akbarzadeh A, Alimirzalu S, Rahmati Yamchi M, Barkhordari A, Tozihi M, Kordi SH, Mohammadzadeh N, FekriAval S, NaderyMahabady F, et al. Study of inhibitory effect of β-cyclodex-rin-helenalincomplex on HTERT gene expression in T47D breast cancer cell line by real time quantitative PCR (q-PCR). APJCP, 2013;14(11):6949-53.
20. Gill S, Löbenberg R, Ku T, Azarmi S, Roa W, Prenner EJ. Nanoparticles: Characteristics, mechanisms of action and toxicity in pulmonary drug delivery - A review. J Biomed Nanotechnol, 2007;3:107-19.
21. Ginsberg RJ, Vokes EE, Rosenzweig K. 2001. Non-small cell lung cancer. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. Cancer: Principles and practices of oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, pp. 925-82.
22. Hasani A, Sharifi Y, Ghotaslou R, Naghili B, Aghazadeh M, Milani M, Bazmani A. Molecular screening of virulence genes in high-level gentamicin-resistant Enterococcus faecalis and Enterococcus faecium isolated from clinical specimens in Northwest Iran. Ind J Med Microbiol, 2012;30(2):175-83.
23. Kazem N-K, Abolfazl A, Mohammad P-M, San WJ. Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. APJCP, 2013;14(11):65-95.
24. Lee CT, Kang KH, Koh Y, Chang J, Chung HS, Park SK, Yoo K, Song JS. Characteristics of lung cancerin Korea, 1997. Lung Cancer, 2000;30:15-22.
25. Lotfipour F, Abdollahi S, Jelvehgari M, Valizadeh H, Hassan M, Milani M. Study of antimicrobial effects of vancomycin loaded PLGA nanoparticles against enterococcus clinical isolates. Drug Res, 2013;64(6):281-8.
26. Mohammad P-M, Mohammad R-Y, Abolfazl A, Hadis D, Kazem N-K, Younes H, Sang WJ. Protein detection through different platforms of immuno-loop-mediated isothermal amplification. Nanoscale Res Lett, 2013;8:485-95.
27. Mohammad K, Ali V, Abolfazl A, Younes H, Sang WJ. Investigation of quadratic electro-optic effects and electro absorption process in GaN/AlGaN spherical quantum dot. Nanoscale Res Lett, 2014a;9(1):1-6.
28. Mohammad P-M, Nosratollah Z, Afshin M, Mohammad R-Y, Davud G, Abolfazl A, de la Guardia M, Kazem N-K. Watercress-based gold nanoparticles: Biosynthesis, mechanism of formation and study of their biocompatibility in vitro. Micro Nano Lett, 2014b;9(5):345-50.
29. Mollazade M, Nejati-Koshki K, Abolfazl A, Younes H, Zarghami N, Sang WJ. PAMAM dendrimers arugment inhibitory effect of curcumin on cancer cell proliferation: Possible inhibition of telomerase. APJCP, 2013;14(11):6925-8.
30. Mortaza TA, Fatemeh STM, Mahmoud I, Vahideh Z, Fariba B, Roya S, Nosratollah Z, Masoud D, Abolfazl A, Mohammad R-Y. The comparison between effects of free curcumin and curcumin loaded PLGA-PEG on telomerase and TRF1 expressions in calu-6 lung cancer cell line. Int J Biosci, 2014;4(10):134-45.
31. Quattrin T. Inhaled insulin: Recent advances in the therapy of Type 1 and 2 diabetes. Expert Opin Pharmacother, 2004;5(12):2597-604.
32. Rogaie R-S, Nosratollah Z, Abolfazl B, Akram E, Abolfazl A, Mustafa R-T. Studies of the relationship between structure and antioxidant activity in interesting systems, including tyrosol, hydroxytyrosol derivatives indicated by quantum chemical calculations. Soft, 2013;2:13-18.
33. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer, 2011;12(1):68-78.
34. Samira A, Abolfazl A, Mojtaba A, Somayeh A, Soodabeh D, Younes H, Mohammad S, Sang WJ. Synthesis and study of physicochemical characteristics of Fe3O4 magnetic nanocomposites based on poly(Nisopropylacrylamide)for anti-cancer drugs delivery. Asian Pac J Cancer Prev, 2014;15(1):049-54.
35. Sara H, Roghiyeh P, Amir AK, Hamid TN, Kazem N-K, Abolfazl A, Sang WJ, Younes H, Soodabeh D. Synthesis, characterization, and in vitro studies of PLGA-PEG nanoparticles for oral insulin delivery. Chem Biol Drug Design, 2014;84(2):200(1-11).
36. Taylor G, Kellaway I. 2001. Pulmonary drug delivery. In: Hillery A, Lloyd A, Swarbrick J, eds. Drug delivery and targeting. New York: Taylor & Francis, pp. 269-300.
37. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojanparticles: Large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci, 2002;99:12001-5.
38. Valizadeh H, Mohammadi G, Ehyaei R, Milani M, Azhdarzadeh M, Zakeri-Milani P, Lotfipour F. Antibacterial activity of clarithromycin loaded PLGA nanoparticles. Die Pharmazie-Int J Pharmaceut Sci, 2012a;67(1):63-8.
39. Valizadeh H, Mohammadi G, Ehyaei R, Milani M, Azhdarzadeh M, Zakeri-Milani P, Lotfipour F. Antibacterial activity of clarithromycin loaded PLGA nanoparticles. Die Pharmazie-Int J Pharmaceut Sci, 2012b;67(1):63-8.
40. Yaeghob S, Alka H, Reza G, Mojtaba V, Akbar H, Mohammad HS, Mohammad A, Morteza M. Vancomycin-resistant enterococci among clinical isolates from north-west Iran: Identification of therapeutic surrogates. J Med Microbiol, 2012;61(4):600-2.
41. Zahra D, Abolfazl A, Mohammad R, AliAkbar M, Mohsen A, Kazem N-K, Zohre S, Hassan D, Nosratollah Z. Molecular target therapy of Akt and NF-kB signaling pathways and multidrug resistance by specific cell penetrating inhibitor peptides in HL-60 cell line. APJCP, 2014;9:4353-8.
42. 4 in T47D Breast Cancer Cell Line. BioImpacts, 2013;3(2):67-74.